Ning Shufang, Liu Haizhou, Gao Bing, Wei Wene, Yang Aifang, Li Jilin, Zhang Litu
Department of Research, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Oncol Lett. 2019 Sep;18(3):3381-3387. doi: 10.3892/ol.2019.10606. Epub 2019 Jul 11.
Increasing evidence has demonstrated that circulating microRNAs (miRNAs) can be utilized as potential biomarkers for the diagnosis of cancer, as well as a prognostic tool for the management of the disease. Therefore, the present study aimed to evaluate the predictive ability of miRNA (miR)-155, miR-96 and miR-99a for the diagnosis and prognosis of hepatocellular carcinoma (HCC). Tissues were collected from 30 patients with HCC and their matched adjacent normal liver tissues, as well as from serum samples from 30 patients with HCC and 30 healthy controls. Reverse transcription-quantitative PCR was used to measure the expression levels of miR-155, miR-96 and miR-99a. The expression levels of miR-155 and miR-96 were upregulated in the tissues and serum of patients with HCC, whereas miR-99a expression levels were decreased. Receiver operating characteristics (ROC) curve analysis revealed that circulating miR-155, miR-96, miR-99a and a combination of these three miRNAs could serve as diagnostic biomarkers for HCC with areas under the curve (AUC) of 0.84, 0.824, 0.799 and 0.931, respectively. Serum α-fetoprotein (AFP) was detected using electrochemiluminescence immunoassay analyzer. The addition of AFP with the combination of these three miRNAs offered a higher accuracy of HCC diagnosis (AUC, 0.979; sensitivity, 90.0%; specificity, 100.0%). In addition, elevated expression levels of miR-155 and miR-96 were associated with poor survival time of patients with HCC. The panel of miR-155, miR-96, miR-99a and AFP had a higher sensitivity and specificity for the diagnosis of HCC when compared with a single marker. Furthermore, the present data suggested that miR-155 and miR-96 may be potential prognostic markers for the clinical management of patients with HCC.
越来越多的证据表明，循环微RNA（miRNA）可作为癌症诊断的潜在生物标志物，以及疾病管理的预后工具。因此，本研究旨在评估miRNA（miR）-155、miR-96和miR-99a对肝细胞癌（HCC）诊断和预后的预测能力。收集了30例HCC患者及其配对的相邻正常肝组织，以及30例HCC患者和30例健康对照的血清样本。采用逆转录定量PCR检测miR-155、miR-96和miR-99a的表达水平。HCC患者组织和血清中miR-155和miR-96的表达水平上调，而miR-99a表达水平降低。受试者工作特征（ROC）曲线分析显示，循环miR-155、miR-96、miR-99a以及这三种miRNA的组合可作为HCC的诊断生物标志物，曲线下面积（AUC）分别为0.84、0.824、0.799和0.931。采用电化学发光免疫分析仪检测血清甲胎蛋白（AFP）。AFP与这三种miRNA的组合对HCC诊断具有更高的准确性（AUC，0.979；敏感性，90.0%；特异性，100.0%）。此外，miR-155和miR-96表达水平升高与HCC患者生存时间短相关。与单一标志物相比，miR-155、miR-96、miR-99a和AFP组合对HCC诊断具有更高的敏感性和特异性。此外，本数据表明，miR-155和miR-96可能是HCC患者临床管理的潜在预后标志物。
